Tag: Bayer
Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary artery disease
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and myocardial infarction in patients with coronary artery disease
The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–...
AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients with atrial fibrillation
Two drug regimens involving low doses of rivaroxaban (Xarelto, Bayer)—one with a 15mg once daily...
